GLP-1 Drugs (U.S.): 2025 Pulse Survey
The Pulse Survey: GLP-1 Drugs explores how U.S. employers are approaching coverage and decision-making related to GLP-1 medications, traditionally used to treat diabetes and support weight loss. Findings show that these drugs now account for more than 10% of annual claims. Employers are primarily relying on utilization management and eligibility criteria to control costs. The International Foundation conducted the survey initially in October 2023 and repeated it in May 2024.
The graphs below reflect corporate plan responses
There's more! View a full listing of International Foundation benchmarking and pulse survey reports.
Survey reports are just one of the many helpful products and services included with an International Foundation membership.